Lacosamide Stada

Lacosamide, the active ingredient in Lacosamide Stada, is a sodium channel blocker presented as an oral tablet for oral use. It is employed to treat partial‑onset seizures in patients with epilepsy, helping to reduce seizure frequency and improve overall seizure control. The medication modulates neuronal excitability by enhancing the slow inactivation of voltage‑gated sodium channels and is approved for use as an adjunctive therapy in both adult and pediatric populations.

GNH USA supplies Lacosamide Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug that acts on neuronal sodium channels to manage seizure disorders.

- Partial‑onset seizures: adjunctive therapy to reduce seizure frequency. - Focal epilepsy: improves overall seizure control when added to existing regimens. - Refractory focal seizures: offers an alternative mechanism for patients not responding to other antiepileptics.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild gastrointestinal upset. - Headache: occasional mild to moderate pain. - Fatigue: feeling unusually tired. - Blurred vision: temporary visual disturbances. - Somnolence: increased sleepiness.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmia. - Suicidal ideation: emergence of depressive thoughts. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypersensitivity: rash, angioedema, or anaphylaxis. - Hepatic enzyme elevation: abnormal liver function tests. - Seizure worsening: rare increase in seizure frequency.

When prescribing Lacosamide, several safety considerations should be observed.

- Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction: obtain baseline ECG and monitor PR interval during therapy. - Pregnancy: limited data; weigh potential benefits against unknown fetal risks. - Concomitant sodium‑channel blockers: avoid or use with caution due to additive effects. - Driving and operating machinery: advise patients of possible dizziness or somnolence. - Store at ambient temperature: keep below 25°C, in original packaging, protected from moisture.

Lacosamide can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin): may markedly lower lacosamide plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin): may increase lacosamide exposure and risk of adverse effects. - Other sodium‑channel blockers (e.g., oxcarbazepine, lamotrigine): may potentiate cardiac conduction effects.

Moderate Interactions (Monitor Closely): - Oral contraceptives: lacosamide may reduce hormonal efficacy; advise alternative contraception. - Antacids: may affect absorption; separate administration by at least 2 hours. - Alcohol: additive CNS depression; counsel patients on limited intake. - Other antiepileptics: dose adjustments may be required based on therapeutic response.